Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma

Blood

Volumn 123, Issue 12, 2014, Pages 1836-1849

  Franco, Giovanni ^a   Guarnotta, Carla ^a   Frossi, Barbara ^b   Piccaluga, Pier Paolo ^c   Boveri, Emanuela ^d   Gulino, Alessandro ^a   Fuligni, Fabio ^c   Rigoni, Alice ^e   Porcasi, Rossana ^a   Buffa, Salvatore ^a   Betto, Elena ^b   Florena, Ada Maria ^a   Franco, Vito ^a   Iannitto, Emilio ^a   Arcaini, Luca ^d   Pileri, Stefano Aldo ^c   Pucillo, Carlo ^b   Colombo, Mario Paolo ^e   Sangaletti, Sabina ^e   Tripodo, Claudio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CD40 ANTIGEN; CD40 LIGAND; CYCLOPHOSPHAMIDE; HYDROXYDAUNORUBICIN; PREDNISONE; PROTEIN P53; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CANCER DIAGNOSIS; CANCER PROGNOSIS; CELL INFILTRATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MAST CELL; MESENCHYMAL STROMA CELL; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; STROMA; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD40; B-LYMPHOCYTES; CD40 LIGAND; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENES, P53; HUMANS; INFLAMMATION MEDIATORS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MAST CELLS; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MIDDLE AGED; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 84897512258     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-497271     Document Type: Article

References (46)

1. Swerdlow S-H, Campo E, Harris N-L, et al. WHO Classification of Tumours of Haemopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
2. Franco V, Florena A-M, Iannitto E. Splenic marginal zone lymphoma. Blood. 2003;101(7):2464-2472. (Pubitemid 36857599)
3. Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 2003;4(2):95-103. (Pubitemid 36193169)
4. Matutes E. Splenic marginal zone lymphoma with and without villous lymphocytes. Curr Treat Options Oncol. 2007;8(2):109-116.
5. Iannitto E, Tripodo C. How I diagnose and treat splenic lymphomas. Blood. 2011;117(9):2585-2595.
6. Franco V, Florena A-M, Campesi G. Intrasinusoidal bone marrow infiltration: a possible hallmark of splenic lymphoma. Histopathology. 1996;29(6):571-575. (Pubitemid 26422832)
7. Ponzoni M, Kanellis G, Pouliou E, et al. Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology? Am J Surg Pathol. 2012;36(11):1609-1618.
8. Boveri E, Arcaini L, Merli M, et al. Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. Ann Oncol. 2009;20(1):129-136.
9. Rinaldi A, Mian M, Chigrinova E, et al. Genomewide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood. 2011;117(5):1595-1604.
10. Salido M, Baró C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood. 2010;116(9):1479-1488.
11. Iannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer. 2004;101(9):2050-2057. (Pubitemid 39425382)
12. Arcaini L, Lazzarino M, Colombo N, et al Integruppo Italiano Linfomi. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107(12):4643-4649. (Pubitemid 43882609)
13. Swartz M-A, Iida N, Roberts E-W, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res. 2012;72(10):2473-2480.
14. Tripodo C, Sangaletti S, Piccaluga P-P, et al. The bone marrow stroma in hematological neoplasms - a guilty bystander. Nat Rev Clin Oncol. 2011;8(8):456-466.
15. Cacciatore M, Guarnotta C, Calvaruso M, et al. Microenvironment-centred dynamics in aggressive B-cell lymphomas. Adv Hematol. 2012;2012:138079.
16. Farinha P, Masoudi H, Skinnider B-F, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106(6):2169-2174. (Pubitemid 41291735)
17. Steidl C, Lee T, Shah S-P, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-885.
18. Maffei R, Bulgarelli J, Fiorcari S, et al. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica. 2013;98(7):1115-1123.
19. Merluzzi S, Frossi B, Gri G, Parusso S, Tripodo C, Pucillo C. Mast cells enhance proliferation of B lymphocytes and drive their differentiation toward IgA-secreting plasma cells. Blood. 2010;115(14):2810-2817.
20. Tournilhac O, Santos D-D, Xu L, et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol. 2006;17(8):1275-1282. (Pubitemid 44288218)
21. Burger J-A, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-3375.
22. Zucchetto A, Benedetti D, Tripodo C, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res. 2009;69(9):4001-4009.
23. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68(13):5439-5449.
24. Yang Z-Z, Novak A-J, Ziesmer S-C, Witzig T-E, Ansell S-M. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2009;69(13):5522-5530.
25. Tripodo C, Gri G, Piccaluga P-P, et al. Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010;177(2):792-802.
26. Franco V, Florena A-M, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer. 2001;91(2):294-301. (Pubitemid 32099229)
27. Tripodo C, Di Bernardo A, Ternullo M-P, et al. CD146(1) bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis. Haematologica. 2009;94(1):127-130.
28. Henn V, Slupsky J-R, Gräfe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391(6667):591-594. (Pubitemid 28157601)
29. Fries K-M, Sempowski G-D, Gaspari A-A, Blieden T, Looney R-J, Phipps R-P. CD40 expression by human fibroblasts. Clin Immunol Immunopathol. 1995;77(1):42-51.
30. Rodríguez MC, Bernad A, Aracil M. Interleukin-6 deficiency affects bone marrow stromal precursors, resulting in defective hematopoietic support. Blood. 2004;103(9):3349-3354. (Pubitemid 38525663)
31. Ward J-M, Tadesse-Heath L, Perkins S-N, Chattopadhyay S-K, Hursting S-D, Morse H-C III. Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice. Lab Invest. 1999;79(1):3-14. (Pubitemid 29063758)
32. Gostissa M, Bianco J-M, Malkin D-J, et al. Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas. Proc Natl Acad Sci U S A. 2013;110(8):2934-2939.
33. Rossi D, Deaglio S, Dominguez-Sola D, et al. Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood. 2011;118(18):4930-4934.
34. Florena A-M, Tripodo C, Porcasi R, et al. Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement. Leuk Lymphoma. 2006;47(1):49-57. (Pubitemid 43101724)
35. Tripodo C, Iannitto E, Florena A-M, et al. Gamma-delta T-cell lymphomas. Nat Rev Clin Oncol. 2009;6(12):707-717.
36. Torlakovic E, Tenstad E, Funderud S, Rian E. CD10 1 stromal cells form B-lymphocyte maturation niches in the human bone marrow. J Pathol. 2005;205(3):311-317. (Pubitemid 40253921)
37. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977-988. (Pubitemid 44894948)
38. Colmone A, Amorim M, Pontier A-L, Wang S, Jablonski E, Sipkins D-A. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322(5909):1861-1865.
39. Gri G, Frossi B, D'Inca F, et al. Mast cell: an emerging partner in immune interaction. Front Immunol. 2012;3:120.
40. Pittoni P, Colombo M-P. The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res. 2012;72(4):831-835.
41. Wilkins B-S, Buchan S-L, Webster J, Jones D-B. Tryptase-positive mast cells accompany lymphocytic as well as lymphoplasmacytic lymphoma infiltrates in bone marrow trephine biopsies. Histopathology. 2001;39(2):150-155. (Pubitemid 34225041)
42. Molin D, Fischer M, Xiang Z, et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol. 2001;114(3):616-623. (Pubitemid 32953640)
43. Brown J-M, Nemeth K, Kushnir-Sukhov N-M, Metcalfe D-D, Mezey E. Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin Exp Allergy. 2011;41(4):526-534.
44. Gri G, Piconese S, Frossi B, et al. CD4+ CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008;29(5):771-781.
45. Piconese S, Gri G, Tripodo C, et al. Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood. 2009;114(13):2639-2648.
46. Rabenhorst A, Schlaak M, Heukamp L-C, et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood. 2012;120(10):2042- 2054.